Literature DB >> 21115161

Treatment of primary aldosteronism.

Marcus Quinkler1, Paul M Stewart.   

Abstract

The prevalence of primary hyperaldosteronism approaches 10% of all hypertensive patients, and besides efficient diagnostic procedures, effective treatment is of increasing importance to reverse increased morbidity and mortality. Aldosterone-producing adenoma and unilateral adrenal hyperplasia are amenable to cure by endoscopic adrenalectomy. Bilateral adrenal hyperplasia (micro- or macronodular), which comprises two-thirds of primary hyperaldosteronism, is treated primarily by mineralocorticoid receptor antagonists (starting dose 12.5-25mg/day spironolactone with titration up to 100mg/day, alternatively 50-100mg/day eplerenone). If blood pressure is not normalised by this first-line treatment, additional treatment with potassium-sparing diuretics (amiloride or triamterene) or calcium channel antagonists is necessary. The start of medication should be closely monitored by serum electrolyte and creatinine controls. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21115161     DOI: 10.1016/j.beem.2010.10.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  6 in total

1.  ENaC inhibition stimulates HCl secretion in the mouse cortical collecting duct. I. Stilbene-sensitive Cl- secretion.

Authors:  Masayoshi Nanami; Yoskaly Lazo-Fernandez; Vladimir Pech; Jill W Verlander; Diana Agazatian; Alan M Weinstein; Hui-Fang Bao; Douglas C Eaton; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-29

2.  ENaC inhibition stimulates Cl- secretion in the mouse cortical collecting duct through an NKCC1-dependent mechanism.

Authors:  Vladimir Pech; Monika Thumova; Young Hee Kim; Diana Agazatian; Edith Hummler; Bernard C Rossier; Alan M Weinstein; Masayoshi Nanami; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-11

3.  Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.

Authors:  Shigehiro Karashima; Takashi Yoneda; Mitsuhiro Kometani; Masashi Ohe; Shunsuke Mori; Toshitaka Sawamura; Kenji Furukawa; Takashi Seta; Masakazu Yamagishi; Yoshiyu Takeda
Journal:  Hypertens Res       Date:  2015-11-26       Impact factor: 3.872

4.  Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

Review 5.  Resistant hypertension: current status, future challenges.

Authors:  Niloofar Hajizadeh; Farahnak Assadi
Journal:  Int J Prev Med       Date:  2014-03

6.  [Tetraparesis revealing Conn adenoma in a pregnant woman].

Authors:  Naoufal Assoufi; Nessrine Bahadi; Nawal El Omri; Youssef Sekkach; Taoufiq Ameziane; Driss Ghafir
Journal:  Pan Afr Med J       Date:  2016-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.